Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania

Michael H. Allen, Robert M. Hirschfeld, Patricia J. Wozniak, Jeffrey D. Baker, Charles L. Bowden

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Objective: Several studies have shown that achieving adequate serum valproate levels is critical to rapid stabilization of acute mania, but estimates of the target therapeutic level have been imprecise. A post hoc analysis of pooled intent-to-treat data from three randomized, placebo-controlled studies of divalproex treatment for acute mania was performed to test a hypothesized linear relationship between serum concentration and response and to determine optimal blood levels for treatment of acute mania. Method: Subjects (N=374) were stratified into seven groups (six valproate serum level ranges and placebo), and effect size was determined for each. Linearity of dose response was tested with both parametric and nonparametric techniques. ANOVA was used to compare the response at each serum level range with that of placebo as well as the lowest valproate level (≤55.0 μg/ml). The mean serum valproate level was then determined for all subjects with an effect size greater than or equal to the maximal effect derived from linear modeling. Results: The fit of blood level and response to a linear model was good. Efficacy was significantly greater than placebo beginning at the 71.4-85.0 μg/ml range and for all higher valproate levels; the 94.1-107.0 and >107.0 μg/ml groups were superior to the lowest valproate serum level group. The effect size associated with highest serum levels (>94 μg/ml) was 1.06 (0.59 after placebo correction). Subjects obtaining this effect or greater (N= 84) had a mean serum level of 87.5 μg/ ml. Blood levels in the lowest effective range were 60% more effective than placebo and in the higher ranges were 120% more effective. Tolerability appeared similar for all groups. Conclusions: The results of this study suggest that there is a linear relationship between valproate serum concentration and response and that the target blood level of valproate for best response in acute mania is above 94 μg/ml.

Original languageEnglish (US)
Pages (from-to)272-275
Number of pages4
JournalAmerican Journal of Psychiatry
Volume163
Issue number2
DOIs
StatePublished - Feb 2006

Fingerprint

Valproic Acid
Bipolar Disorder
Serum
Placebos
Placebo Effect
Linear Models
Analysis of Variance
Therapeutics

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania. / Allen, Michael H.; Hirschfeld, Robert M.; Wozniak, Patricia J.; Baker, Jeffrey D.; Bowden, Charles L.

In: American Journal of Psychiatry, Vol. 163, No. 2, 02.2006, p. 272-275.

Research output: Contribution to journalArticle

Allen, Michael H. ; Hirschfeld, Robert M. ; Wozniak, Patricia J. ; Baker, Jeffrey D. ; Bowden, Charles L. / Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania. In: American Journal of Psychiatry. 2006 ; Vol. 163, No. 2. pp. 272-275.
@article{cadf9130a3614e4cb8e7e080b07c166b,
title = "Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania",
abstract = "Objective: Several studies have shown that achieving adequate serum valproate levels is critical to rapid stabilization of acute mania, but estimates of the target therapeutic level have been imprecise. A post hoc analysis of pooled intent-to-treat data from three randomized, placebo-controlled studies of divalproex treatment for acute mania was performed to test a hypothesized linear relationship between serum concentration and response and to determine optimal blood levels for treatment of acute mania. Method: Subjects (N=374) were stratified into seven groups (six valproate serum level ranges and placebo), and effect size was determined for each. Linearity of dose response was tested with both parametric and nonparametric techniques. ANOVA was used to compare the response at each serum level range with that of placebo as well as the lowest valproate level (≤55.0 μg/ml). The mean serum valproate level was then determined for all subjects with an effect size greater than or equal to the maximal effect derived from linear modeling. Results: The fit of blood level and response to a linear model was good. Efficacy was significantly greater than placebo beginning at the 71.4-85.0 μg/ml range and for all higher valproate levels; the 94.1-107.0 and >107.0 μg/ml groups were superior to the lowest valproate serum level group. The effect size associated with highest serum levels (>94 μg/ml) was 1.06 (0.59 after placebo correction). Subjects obtaining this effect or greater (N= 84) had a mean serum level of 87.5 μg/ ml. Blood levels in the lowest effective range were 60{\%} more effective than placebo and in the higher ranges were 120{\%} more effective. Tolerability appeared similar for all groups. Conclusions: The results of this study suggest that there is a linear relationship between valproate serum concentration and response and that the target blood level of valproate for best response in acute mania is above 94 μg/ml.",
author = "Allen, {Michael H.} and Hirschfeld, {Robert M.} and Wozniak, {Patricia J.} and Baker, {Jeffrey D.} and Bowden, {Charles L.}",
year = "2006",
month = "2",
doi = "10.1176/appi.ajp.163.2.272",
language = "English (US)",
volume = "163",
pages = "272--275",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "2",

}

TY - JOUR

T1 - Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania

AU - Allen, Michael H.

AU - Hirschfeld, Robert M.

AU - Wozniak, Patricia J.

AU - Baker, Jeffrey D.

AU - Bowden, Charles L.

PY - 2006/2

Y1 - 2006/2

N2 - Objective: Several studies have shown that achieving adequate serum valproate levels is critical to rapid stabilization of acute mania, but estimates of the target therapeutic level have been imprecise. A post hoc analysis of pooled intent-to-treat data from three randomized, placebo-controlled studies of divalproex treatment for acute mania was performed to test a hypothesized linear relationship between serum concentration and response and to determine optimal blood levels for treatment of acute mania. Method: Subjects (N=374) were stratified into seven groups (six valproate serum level ranges and placebo), and effect size was determined for each. Linearity of dose response was tested with both parametric and nonparametric techniques. ANOVA was used to compare the response at each serum level range with that of placebo as well as the lowest valproate level (≤55.0 μg/ml). The mean serum valproate level was then determined for all subjects with an effect size greater than or equal to the maximal effect derived from linear modeling. Results: The fit of blood level and response to a linear model was good. Efficacy was significantly greater than placebo beginning at the 71.4-85.0 μg/ml range and for all higher valproate levels; the 94.1-107.0 and >107.0 μg/ml groups were superior to the lowest valproate serum level group. The effect size associated with highest serum levels (>94 μg/ml) was 1.06 (0.59 after placebo correction). Subjects obtaining this effect or greater (N= 84) had a mean serum level of 87.5 μg/ ml. Blood levels in the lowest effective range were 60% more effective than placebo and in the higher ranges were 120% more effective. Tolerability appeared similar for all groups. Conclusions: The results of this study suggest that there is a linear relationship between valproate serum concentration and response and that the target blood level of valproate for best response in acute mania is above 94 μg/ml.

AB - Objective: Several studies have shown that achieving adequate serum valproate levels is critical to rapid stabilization of acute mania, but estimates of the target therapeutic level have been imprecise. A post hoc analysis of pooled intent-to-treat data from three randomized, placebo-controlled studies of divalproex treatment for acute mania was performed to test a hypothesized linear relationship between serum concentration and response and to determine optimal blood levels for treatment of acute mania. Method: Subjects (N=374) were stratified into seven groups (six valproate serum level ranges and placebo), and effect size was determined for each. Linearity of dose response was tested with both parametric and nonparametric techniques. ANOVA was used to compare the response at each serum level range with that of placebo as well as the lowest valproate level (≤55.0 μg/ml). The mean serum valproate level was then determined for all subjects with an effect size greater than or equal to the maximal effect derived from linear modeling. Results: The fit of blood level and response to a linear model was good. Efficacy was significantly greater than placebo beginning at the 71.4-85.0 μg/ml range and for all higher valproate levels; the 94.1-107.0 and >107.0 μg/ml groups were superior to the lowest valproate serum level group. The effect size associated with highest serum levels (>94 μg/ml) was 1.06 (0.59 after placebo correction). Subjects obtaining this effect or greater (N= 84) had a mean serum level of 87.5 μg/ ml. Blood levels in the lowest effective range were 60% more effective than placebo and in the higher ranges were 120% more effective. Tolerability appeared similar for all groups. Conclusions: The results of this study suggest that there is a linear relationship between valproate serum concentration and response and that the target blood level of valproate for best response in acute mania is above 94 μg/ml.

UR - http://www.scopus.com/inward/record.url?scp=33644995586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644995586&partnerID=8YFLogxK

U2 - 10.1176/appi.ajp.163.2.272

DO - 10.1176/appi.ajp.163.2.272

M3 - Article

C2 - 16449481

AN - SCOPUS:33644995586

VL - 163

SP - 272

EP - 275

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 2

ER -